| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. | EVP, Research and Development | Common Stock | 319K | $1.95M | $6.10 | Feb 27, 2024 | Direct |
| GW PHARMACEUTICALS PLC | Chief Medical Officer | Ordinary Shares | 0 | May 5, 2021 | Direct | ||
| GW PHARMACEUTICALS PLC | Chief Medical Officer | Share Options | 0 | May 5, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | Feb 27, 2024 | 1 | -$30.1K | 4 | Feb 29, 2024 | EVP, Research and Development |
| AUPH | Aurinia Pharmaceuticals Inc. | Feb 20, 2024 | 1 | -$138K | 4 | Feb 22, 2024 | EVP, Research and Development |
| AUPH | Aurinia Pharmaceuticals Inc. | Mar 2, 2023 | 1 | $0 | 4 | Mar 6, 2023 | EVP, Research and Development |
| AUPH | Aurinia Pharmaceuticals Inc. | Aug 1, 2022 | 2 | $0 | 4 | Aug 1, 2022 | EVP, Research and Development |
| AUPH | Aurinia Pharmaceuticals Inc. | Jul 18, 2022 | 0 | $0 | 3 | Jul 19, 2022 | EVP, Research and Development |
| GWPH | GW PHARMACEUTICALS PLC | May 5, 2021 | 12 | $0 | 4 | May 7, 2021 | Chief Medical Officer |